Wire · operational-macro
United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 October 2026 · Fusion42 review
United Therapeutics received FDA clearance to begin a clinical trial for Treprostinil-Iloprost SMI, a novel inhaled combination therapy designed for on-demand symptom relief in pulmonary arterial hypertension patients. The phase 1 trial will assess safety, tolerability, and pharmacokinetics before a planned phase 2 trial in PAH patients.
This Wire brief sits within Fusion42's coverage of Health, and 1 source has reported it between 19 Oct 2026 and 28 Oct 2026.
◆ ◆ The Wire takeaway
You now have a regulatory window to develop on-demand inhaled therapies for pulmonary arterial hypertension, a niche with urgent patient needs. This clearance opens the rare opportunity to be first in an unserved market segment for episodic symptom relief.
◆ Coverage
1 source · first reported 19 Oct 2026 · latest 28 Oct 2026
◆ Related on Wire
◆ Topics